The Green Cross Corporation

Senju Pharmaceutical Co., Ltd.

Jcr Pharmaceuticals Co., Ltd.

Nihon Chemical Research Co., Ltd.

Hiromichi Ishikawa

Tetsuo Matsui

Yoshiyuki Nakamura

Tomoji Aotsuka

Hiroshi Hosono

Takema Hase

Takahiro Kumonaka

Toshiyuki Nishio

Toshio Kurihara

Fujio Kobayashi

Satoshi Nishimuro

Keihide Koh

Yoshikazu Komurasaki

Shinichi Koni

Sei Kirihara

Koichi Sugita

Mitsuru Hirota

Yutaka Igarashi

Tomoko Watanabe

Mitsugu Fujita

Chikako Shimizu

An injection syringe generally comprised of a multichambered cylindrical ampule, a tripartite case of a front case; a middle case; a rear case, and a needle-holder, and a plunger: the multichambered cylindrical ampule including two chambers of a front space and a rear space, the front space being sealed forwardly with a packing penetrable by a needle and sealed rearwardly with a movable front gasket, and the rear space being sealed forwardly with the front gasket and sealed rearwardly with a movable rear gasket, and the ampule also including a bypass route longitudinally arranged on inner surface of the ampule such that the front gasket is located to take a position rearwardly apart from the bypass route before dissolution of a solid medicine, wherein the front space for admission of the solid medicine is separated from the rear space for admission of a medicinal solvent or dispersing agent; the middle case also including a short thread or fixer means provided externally at midportion thereof, and the rear case including another short thread or fixer means provided internally at the front end thereof. The present invention brings out the merits of facilitating injections in the use of unstable chemicals, and avoiding possible inclusion of foreign matters or microorganisms, and overcoming misoperations possible during complex preparation procedure, inability to comply with an urgent case, such are attendant defects with traditional injection syringes.

Injection syringe

An injection syringe including a device for preparation of an injection in situ, useful to the injection which is liable to suffer chemical changes if left for a long time in the state of solution or dispersion ready to inject. The injection syringe is portable by a patient who may prepare a necessary injection in situ with the use of a device included in the syringe which will automatically perform an injection with a prescribed dosage. The injection syringe includes a device for preparation of an injection, whereby mechanical impacts affecting the medicine and consequently, chemical changes with a medicine would be minimized during the step of dissolving the medicine. The syringe as noted is especially useful for preparation of injection and injection of human growth hormones, interferon and various polypeptides which are of an environmentally sensitive nature and liable to suffer chemical changes if left for a long time in the state of solution or dispersion.

Injection syringe including device for preparation of injection

The present invention provides novel metastasis suppressory agents with a lowered degree of toxicity, comprising ursolic acid or its salt as an active ingredient, which can be administered to patients per os or through injection, thus enabling the patients to receive post-operative ambulatory treatment.

Metastasis suppressory agents

According to the present invention, there are provided suppressory agents against hypercoagulation which comprise as an effective ingredient protein C inhibitor with a molecular weight of 54 to 57 kDa (DS-PAGE) being capable of suppressing function of the blood coagulation system.

Suppressory agents against hypercoagulation

Succinamic acid compound, production method thereof and use thereof

A pyridothiazineacetic acid compound of the formula (I) ##STR1## wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, production thereof, and a pharmaceutical composition, an aldose reductase inhibitor and a preparation for the prevention and treatment of the complications of diabetes, containing the same. The pyridothiazineacetic acid compound and a pharmaceutically acceptable salt thereof of the present invention have an aldose reductase inhibitory action and are superior in safety. Accordingly, they are useful as a preparation for the prevention and treatment of the complications of diabetes, such as faulty union of corneal injury, cataract, neurosis, retinopathy and nephropathy, particularly, cataract and neurosis. In addition, the production method of the present invention enables efficient production of said pyridothiazineacetic acid compound.

Pyridothiazineacetic acid compound, production thereof and use thereof

1,4-benzoxazine-2-acetic acid compound, method for production thereof

Quinoline-3-acetic acid derivative, process for production thereof and

Benzothiazole compound, production thereof and use thereof

Growing community of inventors

Kobe, Japan

Hiromichi Ishikawa